metformin has been researched along with Anoxemia in 39 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study demonstrates that HIF1α stimulates both TG2 expression and activity via ZEB2/TRPC6 axis, whereas abrogation of HIF1α by metformin prevented hypoxia-induced glomerular injury." | 8.31 | Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis. ( Kavvuri, R; Kolligundla, LP; Mukhi, D; Pasupulati, AK; Singh, AK, 2023) |
| "Activated CD8 T cells were exposed to hypoxia and metformin and analyzed by fluorescence-activated cell sorting for cell proliferation, apoptosis and phenotype." | 8.31 | Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. ( Dvorakova, T; Finisguerra, V; Formenti, M; Gallez, B; Mignion, L; Van den Eynde, BJ; Van Meerbeeck, P, 2023) |
| "Metformin metabolism is slowed down in T2DM patients in the hypoxic environment of the plateau; the glucose-lowering effect of the plateau is similar, and the attainment rate is low, the possibility of having serious adverse effects of lactic acidosis is higher in T2DM patients on the plateau than on the control one." | 8.31 | Effects of plateau hypoxia on population pharmacokinetics and pharmacodynamics of metformin in patients with Type 2 diabetes. ( Hu, L; Li, W; Luo, L; Luo, X; Qin, N; Shen, Y; Sun, Y; Wang, R; Wang, Z, 2023) |
| " In this study, we investigated the potential effects of acute systemic hypoxia itself and in combination with metformin on hepatocellular carcinoma (HCC) growth and metastasis in a mouse model of HCC." | 7.96 | Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. ( Huang, Y; Lin, H; Ren, M; Wang, H; Xu, F; Zhou, W, 2020) |
| "Metformin attenuates diabetes-induced renal medullary tissue hypoxia in an animal model of insulinopenic type 1 diabetes." | 7.91 | Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2. ( Christensen, M; Gustafsson, H; Krag, SP; Nørregaard, R; Palm, F; Schiffer, TA, 2019) |
| " Both metformin and resveratrol effectively inhibited HIF-1α activation-induced fibrosis and inflammation in adipose tissue, although by different mechanisms." | 7.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 7.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "To determine the respective role of metformin accumulation and tissue hypoxia in triggering metformin-associated lactic acidosis (MALA), we measured plasma (PM) and red blood cell (RM) metformin concentrations in 14 patients with MALA and in 58 diabetic patients on well-tolerated chronic metformin treatment." | 7.69 | Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis. ( De Cagny, B; Fournier, A; Lacroix, C; Lalau, JD, 1994) |
| "Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies." | 5.91 | Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types. ( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023) |
| "Metformin treatment after hypoxia-ischaemia had no effect on microglia number and proliferation, but significantly reduced microglia activation in all regions examined, concomitant with improved behavioural outcomes in injured mice." | 5.72 | Reduced microglia activation following metformin administration or microglia ablation is sufficient to prevent functional deficits in a mouse model of neonatal stroke. ( Adams, KV; Bourget, C; Morshead, CM, 2022) |
| " Patients underwent screening positron emission tomography (PET) imaging with hypoxia tracer fluoroazomycin arabinoside (FAZA)." | 5.51 | A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. ( Bruce, J; Cairns, R; Chaudary, N; Croke, J; D'Souza, D; Dhani, N; Fyles, A; Han, K; Jaffray, D; Koritzinsky, M; Lee, TY; Metser, U; Milosevic, M; Pakbaz, S; Pintilie, M; Rouzbahman, M; Shek, T; Vines, D, 2022) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 5.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "Metformin is a first-line drug for the management of type 2 diabetes." | 5.43 | Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. ( Chen, M; Hu, M; Liao, H; Yang, F; Ye, P, 2016) |
| "This study demonstrates that HIF1α stimulates both TG2 expression and activity via ZEB2/TRPC6 axis, whereas abrogation of HIF1α by metformin prevented hypoxia-induced glomerular injury." | 4.31 | Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis. ( Kavvuri, R; Kolligundla, LP; Mukhi, D; Pasupulati, AK; Singh, AK, 2023) |
| "Activated CD8 T cells were exposed to hypoxia and metformin and analyzed by fluorescence-activated cell sorting for cell proliferation, apoptosis and phenotype." | 4.31 | Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. ( Dvorakova, T; Finisguerra, V; Formenti, M; Gallez, B; Mignion, L; Van den Eynde, BJ; Van Meerbeeck, P, 2023) |
| "Metformin metabolism is slowed down in T2DM patients in the hypoxic environment of the plateau; the glucose-lowering effect of the plateau is similar, and the attainment rate is low, the possibility of having serious adverse effects of lactic acidosis is higher in T2DM patients on the plateau than on the control one." | 4.31 | Effects of plateau hypoxia on population pharmacokinetics and pharmacodynamics of metformin in patients with Type 2 diabetes. ( Hu, L; Li, W; Luo, L; Luo, X; Qin, N; Shen, Y; Sun, Y; Wang, R; Wang, Z, 2023) |
| " The effect of metformin on HIF-1 activity was analyzed by quantification of HIF target gene expression and HIF-1 protein stabilization in human mesothelial cells and murine fibroblast under normoxia and hypoxia." | 4.12 | Effect of Metformin on HIF-1α Signaling and Postoperative Adhesion Formation. ( Biller, ML; Bleul, M; Dupovac, M; Harnoss, JM; Keppler, U; Probst, P; Schneider, M; Strowitzki, MJ; Tran, DT; Tuffs, C, 2022) |
| " In this study, we investigated the potential effects of acute systemic hypoxia itself and in combination with metformin on hepatocellular carcinoma (HCC) growth and metastasis in a mouse model of HCC." | 3.96 | Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. ( Huang, Y; Lin, H; Ren, M; Wang, H; Xu, F; Zhou, W, 2020) |
| "Metformin attenuates diabetes-induced renal medullary tissue hypoxia in an animal model of insulinopenic type 1 diabetes." | 3.91 | Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2. ( Christensen, M; Gustafsson, H; Krag, SP; Nørregaard, R; Palm, F; Schiffer, TA, 2019) |
| "Previous studies have shown that metformin (MET) prevents experimental pulmonary arterial hypertension (PAH) and that activation of autophagy is involved in the development of pulmonary vascular remodeling." | 3.91 | Metformin Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Activation of Adenosine Monophosphate-Activated Protein Kinase. ( Li, H; Liu, Y; Sun, Z; Xu, Y; Yang, G; Zhang, J; Zhu, J, 2019) |
| " Both metformin and resveratrol effectively inhibited HIF-1α activation-induced fibrosis and inflammation in adipose tissue, although by different mechanisms." | 3.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 3.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "To determine the respective role of metformin accumulation and tissue hypoxia in triggering metformin-associated lactic acidosis (MALA), we measured plasma (PM) and red blood cell (RM) metformin concentrations in 14 patients with MALA and in 58 diabetic patients on well-tolerated chronic metformin treatment." | 3.69 | Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis. ( De Cagny, B; Fournier, A; Lacroix, C; Lalau, JD, 1994) |
| "The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death." | 3.11 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. ( Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A, 2022) |
| "Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies." | 1.91 | Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types. ( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023) |
| "Metformin is a glucose-lowering, insulin-sensitizing drug that is commonly used in the treatment of type 2 diabetes (T2D)." | 1.91 | Chronic Metformin Administration Does Not Alter Carotid Sinus Nerve Activity in Control Rats. ( Conde, SV; Melo, BF; Prieto-Lloret, J; Sacramento, JF, 2023) |
| "Apical periodontitis was induced in mandibular first molars of 10 Sprague-Dawley rats." | 1.91 | Metformin Reduces Bone Resorption in Apical Periodontitis Through Regulation of Osteoblast and Osteoclast Differentiation. ( Chen, MH; Cheng, SJ; Hong, CY; Kok, SH; Lai, EH; Lin, HY; Lin, SK; Shun, CT; Wang, HW; Wu, FY; Yang, CN; Yang, H, 2023) |
| "Metformin treatment after hypoxia-ischaemia had no effect on microglia number and proliferation, but significantly reduced microglia activation in all regions examined, concomitant with improved behavioural outcomes in injured mice." | 1.72 | Reduced microglia activation following metformin administration or microglia ablation is sufficient to prevent functional deficits in a mouse model of neonatal stroke. ( Adams, KV; Bourget, C; Morshead, CM, 2022) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 1.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "Metformin is a first-line drug for the management of type 2 diabetes." | 1.43 | Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. ( Chen, M; Hu, M; Liao, H; Yang, F; Ye, P, 2016) |
| "Metformin (200 mg/kg) was administrated for up to 14 days." | 1.40 | Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. ( Chen, X; Gu, X; Li, Y; Liu, Y; Tang, G; Wang, Y; Yang, GY; Zhang, Z, 2014) |
| "Wildtype C." | 1.37 | Environmental and genetic preconditioning for long-term anoxia responses requires AMPK in Caenorhabditis elegans. ( LaRue, BL; Padilla, PA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 18 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Jankeviciute, S | 1 |
| Svirskiene, N | 2 |
| Svirskis, G | 2 |
| Borutaite, V | 2 |
| Biller, ML | 1 |
| Tuffs, C | 1 |
| Bleul, M | 1 |
| Tran, DT | 1 |
| Dupovac, M | 1 |
| Keppler, U | 1 |
| Harnoss, JM | 1 |
| Probst, P | 1 |
| Schneider, M | 1 |
| Strowitzki, MJ | 1 |
| Bourget, C | 1 |
| Adams, KV | 1 |
| Morshead, CM | 1 |
| Han, K | 1 |
| Fyles, A | 1 |
| Shek, T | 1 |
| Croke, J | 1 |
| Dhani, N | 1 |
| D'Souza, D | 1 |
| Lee, TY | 1 |
| Chaudary, N | 1 |
| Bruce, J | 1 |
| Pintilie, M | 1 |
| Cairns, R | 1 |
| Vines, D | 1 |
| Pakbaz, S | 1 |
| Jaffray, D | 1 |
| Metser, U | 1 |
| Rouzbahman, M | 1 |
| Milosevic, M | 1 |
| Koritzinsky, M | 1 |
| Bramante, CT | 1 |
| Huling, JD | 1 |
| Tignanelli, CJ | 1 |
| Buse, JB | 1 |
| Liebovitz, DM | 1 |
| Nicklas, JM | 1 |
| Cohen, K | 1 |
| Puskarich, MA | 1 |
| Belani, HK | 1 |
| Proper, JL | 1 |
| Siegel, LK | 1 |
| Klatt, NR | 1 |
| Odde, DJ | 1 |
| Luke, DG | 1 |
| Anderson, B | 1 |
| Karger, AB | 1 |
| Ingraham, NE | 1 |
| Hartman, KM | 1 |
| Rao, V | 1 |
| Hagen, AA | 1 |
| Patel, B | 1 |
| Fenno, SL | 1 |
| Avula, N | 1 |
| Reddy, NV | 1 |
| Erickson, SM | 1 |
| Lindberg, S | 1 |
| Fricton, R | 1 |
| Lee, S | 1 |
| Zaman, A | 1 |
| Saveraid, HG | 1 |
| Tordsen, WJ | 1 |
| Pullen, MF | 1 |
| Biros, M | 1 |
| Sherwood, NE | 1 |
| Thompson, JL | 1 |
| Boulware, DR | 1 |
| Murray, TA | 1 |
| Liu, J | 2 |
| Wang, H | 2 |
| Zhang, M | 1 |
| Li, Y | 2 |
| Wang, R | 2 |
| Chen, H | 2 |
| Wang, B | 1 |
| Gao, X | 1 |
| Song, S | 1 |
| Wang, Y | 4 |
| Ren, Y | 1 |
| Li, J | 3 |
| Liu, P | 1 |
| Yang, Z | 1 |
| Qiao, C | 1 |
| Jia, Q | 1 |
| Chen, Z | 1 |
| Wang, X | 1 |
| Liu, X | 1 |
| Zhang, R | 1 |
| Pu, K | 1 |
| Wang, Z | 2 |
| Kolligundla, LP | 1 |
| Kavvuri, R | 1 |
| Singh, AK | 1 |
| Mukhi, D | 1 |
| Pasupulati, AK | 1 |
| Yamaguchi, A | 1 |
| Mukai, Y | 1 |
| Sakuma, T | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Yamada, Y | 1 |
| Kobayashi, M | 1 |
| Finisguerra, V | 1 |
| Dvorakova, T | 1 |
| Formenti, M | 1 |
| Van Meerbeeck, P | 1 |
| Mignion, L | 1 |
| Gallez, B | 1 |
| Van den Eynde, BJ | 1 |
| Sacramento, JF | 1 |
| Melo, BF | 1 |
| Prieto-Lloret, J | 1 |
| Conde, SV | 1 |
| Shen, Y | 1 |
| Luo, X | 1 |
| Qin, N | 1 |
| Hu, L | 1 |
| Luo, L | 1 |
| Sun, Y | 1 |
| Li, W | 1 |
| Hong, CY | 1 |
| Lin, SK | 1 |
| Wang, HW | 1 |
| Shun, CT | 1 |
| Yang, CN | 1 |
| Lai, EH | 1 |
| Cheng, SJ | 1 |
| Chen, MH | 1 |
| Yang, H | 1 |
| Lin, HY | 1 |
| Wu, FY | 1 |
| Kok, SH | 1 |
| Yang, J | 1 |
| Zhang, C | 1 |
| Chen, X | 2 |
| Zhou, D | 1 |
| Sun, Z | 2 |
| Niu, R | 1 |
| Zhu, Y | 1 |
| Wang, L | 2 |
| Chen, Y | 2 |
| Fu, Y | 1 |
| Ma, N | 1 |
| Luo, Y | 1 |
| Tsenova, L | 1 |
| Singhal, A | 1 |
| Lin, H | 1 |
| Zhou, W | 1 |
| Huang, Y | 1 |
| Ren, M | 1 |
| Xu, F | 1 |
| Pampuscenko, K | 1 |
| Roos, FJM | 1 |
| Bijvelds, MJC | 1 |
| Verstegen, MMA | 1 |
| Roest, HP | 1 |
| Metselaar, HJ | 1 |
| Polak, WG | 1 |
| Jonge, HR | 1 |
| IJzermans, JNM | 1 |
| van der Laan, LJW | 1 |
| Yang, Q | 1 |
| Guo, X | 1 |
| Yang, L | 1 |
| Christensen, M | 1 |
| Schiffer, TA | 1 |
| Gustafsson, H | 1 |
| Krag, SP | 1 |
| Nørregaard, R | 1 |
| Palm, F | 1 |
| Zhao, M | 1 |
| Cheng, X | 1 |
| Lin, X | 1 |
| Han, Y | 1 |
| Zhou, Y | 1 |
| Zhao, T | 1 |
| He, Y | 1 |
| Wu, L | 1 |
| Zhao, Y | 1 |
| Fan, M | 1 |
| Zhu, L | 1 |
| Liu, Y | 2 |
| Xu, Y | 1 |
| Zhu, J | 1 |
| Li, H | 1 |
| Zhang, J | 1 |
| Yang, G | 1 |
| Garofalo, C | 1 |
| Capristo, M | 1 |
| Manara, MC | 1 |
| Mancarella, C | 1 |
| Landuzzi, L | 1 |
| Belfiore, A | 1 |
| Lollini, PL | 1 |
| Picci, P | 1 |
| Scotlandi, K | 1 |
| Takiyama, Y | 1 |
| Haneda, M | 1 |
| Tang, G | 1 |
| Gu, X | 1 |
| Zhang, Z | 1 |
| Yang, GY | 1 |
| Zhou, X | 1 |
| Chen, J | 1 |
| Yi, G | 1 |
| Deng, M | 1 |
| Liu, H | 1 |
| Liang, M | 1 |
| Shi, B | 1 |
| Fu, X | 1 |
| Chen, L | 1 |
| He, Z | 1 |
| Wang, J | 1 |
| Houssaini, A | 1 |
| Abid, S | 1 |
| Derumeaux, G | 1 |
| Wan, F | 1 |
| Parpaleix, A | 1 |
| Rideau, D | 1 |
| Marcos, E | 1 |
| Kebe, K | 1 |
| Czibik, G | 1 |
| Sawaki, D | 1 |
| Treins, C | 1 |
| Dubois-Randé, JL | 1 |
| Li, Z | 1 |
| Amsellem, V | 1 |
| Lipskaia, L | 1 |
| Pende, M | 1 |
| Adnot, S | 1 |
| Li, X | 1 |
| Li, A | 2 |
| Qiu, Z | 1 |
| Qi, LW | 1 |
| Kou, J | 1 |
| Liu, K | 2 |
| Liu, B | 2 |
| Huang, F | 1 |
| Desir, S | 1 |
| Dickson, EL | 1 |
| Vogel, RI | 1 |
| Thayanithy, V | 1 |
| Wong, P | 1 |
| Teoh, D | 1 |
| Geller, MA | 1 |
| Steer, CJ | 1 |
| Subramanian, S | 1 |
| Lou, E | 1 |
| Hu, M | 1 |
| Ye, P | 1 |
| Liao, H | 1 |
| Chen, M | 1 |
| Yang, F | 1 |
| Zhao, W | 1 |
| Feng, X | 1 |
| Hou, T | 1 |
| Zhang, N | 1 |
| van den Nouland, DP | 1 |
| Brouwers, MC | 1 |
| Stassen, PM | 1 |
| LaRue, BL | 1 |
| Padilla, PA | 1 |
| Wang, S | 1 |
| Song, P | 1 |
| Zou, MH | 1 |
| Mielke, JG | 1 |
| Taghibiglou, C | 1 |
| Wang, YT | 1 |
| Lalau, JD | 1 |
| Lacroix, C | 1 |
| De Cagny, B | 1 |
| Fournier, A | 1 |
| Cosić, V | 1 |
| Antić, S | 1 |
| Pesić, M | 1 |
| Jovanović, O | 1 |
| Kundalić, S | 1 |
| Djordjević, VB | 1 |
| Duwoos, H | 1 |
| Bertrand, CM | 1 |
| Husson, A | 1 |
| Cramer, J | 1 |
| Tayot, J | 1 |
| Debry, G | 1 |
| Laurent, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
3 reviews available for metformin and Anoxemia
| Article | Year |
|---|---|
Effects of host-directed therapies on the pathology of tuberculosis.
Topics: Host-Pathogen Interactions; Humans; Hypoxia; Metformin; Mycobacterium tuberculosis; Neutrophils; Tub | 2020 |
Hypoxia in diabetic kidneys.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus; Diabetic Nephropathies; Glomerular Filtration Ra | 2014 |
AMP-activated protein kinase, stress responses and cardiovascular diseases.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Cardiovascular Diseases; Cell Proli | 2012 |
2 trials available for metformin and Anoxemia
| Article | Year |
|---|---|
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
Topics: COVID-19; Female; Humans; Hypoxia; Metformin; Nitroimidazoles; Pandemics; Positron Emission Tomograp | 2022 |
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind M | 2022 |
34 other studies available for metformin and Anoxemia
| Article | Year |
|---|---|
Effects of Metformin on Spontaneous Ca
Topics: Animals; Caffeine; Calcium Signaling; Chromans; Cyclosporine; Electron Transport Complex I; Female; | 2021 |
Effect of Metformin on HIF-1α Signaling and Postoperative Adhesion Formation.
Topics: Animals; Humans; Hypoglycemic Agents; Hypoxia; Metformin; Mice; Signal Transduction; Tissue Adhesion | 2022 |
Reduced microglia activation following metformin administration or microglia ablation is sufficient to prevent functional deficits in a mouse model of neonatal stroke.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Hypoxia; Hypoxia-Ischemia, Brain; Metformin; Mice | 2022 |
Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types.
Topics: Animals; Cell Line, Tumor; Endothelin-1; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Metform | 2023 |
Redox dyshomeostasis modulation of the tumor intracellular environment through a metabolic intervention strategy for enhanced photodynamic therapy.
Topics: Buthionine Sulfoximine; Cell Line, Tumor; Glutathione; Humans; Hypoxia; Lipids; Metal-Organic Framew | 2022 |
Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis.
Topics: Animals; Hypoxia; Metformin; Mice; Podocytes; Protein Glutamine gamma Glutamyltransferase 2; Renal I | 2023 |
Monocarboxylate transporter 4 involves in energy metabolism and drug sensitivity in hypoxia.
Topics: Cell Hypoxia; Cell Line, Tumor; Energy Metabolism; Glycolysis; Humans; Hypoxia; Hypoxia-Inducible Fa | 2023 |
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Topics: Animals; CD8-Positive T-Lymphocytes; Humans; Hypoxia; Immunosuppression Therapy; Immunosuppressive A | 2023 |
Chronic Metformin Administration Does Not Alter Carotid Sinus Nerve Activity in Control Rats.
Topics: AMP-Activated Protein Kinases; Animals; Carotid Body; Carotid Sinus; Diabetes Mellitus, Type 2; Hype | 2023 |
Effects of plateau hypoxia on population pharmacokinetics and pharmacodynamics of metformin in patients with Type 2 diabetes.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoxia; Metformin; Tandem Mass Spectr | 2023 |
Metformin Reduces Bone Resorption in Apical Periodontitis Through Regulation of Osteoblast and Osteoclast Differentiation.
Topics: Animals; Bone Resorption; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Hypoxia; Metfor | 2023 |
Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory.
Topics: Humans; Hypoxia; Immunosuppressive Agents; Immunotherapy; Manganese Compounds; Metformin; Neoplasms; | 2023 |
Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hypoxia; Liver Neoplasms; Male; Metformin; Mic | 2020 |
Different effects of metformin and phenformin on hypoxia-induced Ca
Topics: Animals; Calcium; Cytosol; Hypoxia; Male; Metformin; Neurons; Phenformin; Primary Cell Culture; Rats | 2021 |
Impact of hypoxia and AMPK on CFTR-mediated bicarbonate secretion in human cholangiocyte organoids.
Topics: Adolescent; Anoctamin-1; Bicarbonates; Cell Survival; Cystic Fibrosis Transmembrane Conductance Regu | 2021 |
Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Topics: Acetyltransferases; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hep | 2018 |
Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Hypoxia; Kidn | 2019 |
Metformin administration prevents memory impairment induced by hypobaric hypoxia in rats.
Topics: Animals; Apoptosis; Cognition; Hippocampus; Hypoxia; Male; Maze Learning; Memory Disorders; Metformi | 2019 |
Metformin Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Activation of Adenosine Monophosphate-Activated Protein Kinase.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Proteins; Cells, Cultured; Dise | 2019 |
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion.
Topics: AMP-Activated Protein Kinases; Animals; Blood-Brain Barrier; Brain Infarction; Cells, Cultured; Cyto | 2014 |
Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; | 2016 |
Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.
Topics: Animals; Cell Proliferation; Cells, Cultured; Chronic Disease; Gene Deletion; Hyperplasia; Hypertens | 2016 |
The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Fibrosis; | 2016 |
Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Communication; Cell Line, Tumor; Cell Membrane; Co | 2016 |
Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK.
Topics: AMP-Activated Protein Kinases; Animals; Anisomycin; Cell Survival; Cytokines; Electron Transport; Gl | 2016 |
Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Administration, Oral; Animals; Cyclic AMP; Cyclic AMP-Dependent Protei | 2016 |
Prognostic value of plasma lactate levels in a retrospective cohort presenting at a university hospital emergency department.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus; Emergency Service, Hospital; Female; Hospit | 2017 |
Environmental and genetic preconditioning for long-term anoxia responses requires AMPK in Caenorhabditis elegans.
Topics: Adenylate Kinase; Animals; Caenorhabditis elegans; Dietary Carbohydrates; Environment; Escherichia c | 2011 |
Endogenous insulin signaling protects cultured neurons from oxygen-glucose deprivation-induced cell death.
Topics: Animals; Blotting, Western; Cell Death; Cell Survival; Cells, Cultured; Dose-Response Relationship, | 2006 |
Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eryt | 1994 |
Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?
Topics: Antioxidants; Catalase; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hypoxia; Mal | 2001 |
[Reversible hyperlactatemia induced by phenformin with muscular asthenia and cardio-respiratory signs].
Topics: Aged; Animals; Asthenia; Diabetes Complications; Diabetic Ketoacidosis; Dyspnea; Heart Diseases; Hep | 1970 |
[Lactic acidosis and sugar diabetics].
Topics: Alcoholism; Diabetic Ketoacidosis; Humans; Hypoxia; Lactates; Metformin; Phenformin; Starvation | 1970 |